Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Dasatinib

"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~ 1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~ 1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~ 1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00624585 - Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts | Biotech Hunter | Biotech Hunter